214665 Finsbury WWP pp37-pp50 6 15 09 1:30 PM Page 45 Finsbury Worldwide Pharmaceutical Trust PLC Annual Report 2009 45 Notes to the Financial Statements continued 16.
RECONCILIATION OF NET CASH FLOW MOVEMENT TO MOVEMENT IN NET DEBT FUNDS 2009 2008 000 000 Increase decrease in net debt resulting from cashflows 35,950 6,604 Exchange movements 12,042 1,332 Decrease in short term loans bank overdraft 14,813 10,308 Movement in net debt in the year 33,179 18,244 Net funds debt at start of year 2,975 15,269 Net debt funds at end of year 30,204 2,975 Represented by: At 1 April Exchange At 31 March 2008 Cash flows movements 2009 000 000 000 000 Cash at bank 7,050 4,050 1,121 9,979 Bank overdraft 40,000 183 40,183 Bank loans 4,075 14,813 10,738 Net funds debt 2,975 21,137 12,042 30,204 17.
RELATED PARTIES Details of the relationship between the Company, Frostrow Capital LLP and OrbiMed Capital LLC are disclosed in the Report of the Directors on pages 17 and 18.
Samuel D Isaly is a Director of the Company, as well as Managing Partner of the Companys Investment Manager, OrbiMed Capital LLC.
During the year ended 31 March 2009, OrbiMed Capital LLC received 1,667,000 in respect of Investment Management fees, of which 426,000 was outstanding at the year end.
FINANCIAL INSTRUMENTS EXPOSURE TO RISK AND RISK MANAGEMENT POLICIES The Companys financial instruments comprise securities and other investments, derivative instruments, cash balances, loans, debtors and creditors that arise directly from its operations.
As an investment trust, the Company invests in equities and other investments for the long term so as to secure its investment objective as stated on page 14.
In pursuing its investment objective, the Company is exposed to a variety of risks that could result in a reduction in the Companys net assets.
The main risks that the Company faces arising from its financial instruments are: i market risk including foreign currency risk, interest rate risk and other price risk ii liquidity risk iii credit risk These risks and the Directors approach to the management of them, are set out in the Report of Directors on pages 15 and 16 and have not changed from the previous accounting period.
The Investment Manager, in close co-operation with the Board of Directors, co-ordinates the Companys risk management.
